The next level of care in epilepsy: Delays, more delays, delays everywhere

Surgical treatment for drug-resistant epilepsy remains underused in the industrialized world; it is estimated that, in the United States, less than 1% of patients with drug-resistant epilepsy, defined as failure of 2 appropriate trials of antiseizure drugs,1 are referred to an epilepsy center.2 Furthermore, when patients are referred, the delay from onset of epilepsy is 18–22 years,2,3 often too late to prevent irreversible social and psychological disabilities.

Source: Neurology Clinical Practice - August 11, 2019 Category: Neurology Authors: Benbadis, S. R., Engel, J. Tags: Editorial Source Type: research